Lista de obras - Bryan Oronsky - Dominio Público Uruguay

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome

artículo científico publicado en 2017

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

artículo científico publicado en 2016

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.

artículo científico publicado en 2018

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

artículo científico publicado en 2018

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

artículo científico publicado en 2016

A note on improved statistical approaches to account for pseudoprogression

artículo científico publicado en 2018

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

artículo científico publicado en 2018

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

artículo científico publicado en 2016

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors

artículo científico publicado en 2022

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

artículo científico publicado en 2018

CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES

COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making

scientific article published on 19 August 2020

Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice

scientific article published on 03 June 2019

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.

artículo científico publicado en 2018

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

artículo científico publicado en 2016

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

artículo científico publicado en 2015

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

artículo científico publicado en 2016

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report

artículo científico publicado en 2017

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19

artículo científico publicado en 2020

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

artículo científico

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity

artículo científico publicado en 2015

Episensitization: Defying Time's Arrow

artículo científico publicado en 2015

Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients

scientific article published on 01 November 2019

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

artículo científico publicado en 2015

Follow the ATP: tumor energy production: a perspective

artículo científico publicado en 2014

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria

artículo científico publicado en 2015

Going viral: a review of replication-selective oncolytic adenoviruses

artículo científico publicado en 2015

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

artículo científico publicado en 2016

Just eat it: A review of CD47 and SIRP-α antagonism

artículo científico publicado en 2020

Locally advanced rectal cancer: The past, present, and future

artículo científico publicado en 2020

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors

artículo científico publicado en 2017

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

artículo científico publicado en 2016

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

artículo científico publicado en 2015

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

artículo científico publicado en 2017

No patient left behind: The promise of immune priming with epigenetic agents

artículo científico publicado en 2017

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

artículo científico publicado en 2015

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

scientific article published on 24 May 2016

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

artículo científico publicado en 2016

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

artículo científico publicado en 2016

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent

artículo científico publicado en 2012

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

artículo científico publicado en 2016

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

artículo científico publicado en 2019

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

artículo científico publicado en 2017

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

artículo científico publicado en 2016

RRx-001 protects against cisplatin-induced toxicities.

artículo científico publicado en 2017

RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition

scientific article published on 27 June 2019

RRx-001, A novel dinitroazetidine radiosensitizer

artículo científico publicado en 2016

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

artículo científico publicado en 2016

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

artículo científico publicado en 2016

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

artículo científico publicado en 2016

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

artículo científico publicado en 2016

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

artículo científico publicado en 2020

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm

artículo científico publicado en 2013

Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma

scientific article published on 11 December 2020

Rewriting the epigenetic code for tumor resensitization: a review.

artículo científico publicado en 2014

Rockets, radiosensitizers, and RRx-001: an origin story part I.

artículo científico publicado en 2016

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

artículo científico publicado en 2015

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report

artículo científico publicado en 2017

TGF-beta: a master immune regulator

scientific article published on 12 April 2020

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

artículo científico publicado en 2016

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

artículo científico publicado en 2016

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

artículo científico publicado en 2015

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions

artículo científico publicado en 2014

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

artículo científico publicado en 2017

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

artículo científico publicado en 2017

The war on cancer: a military perspective

artículo científico publicado en 2015

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

artículo científico publicado en 2016

What's New in SCLC? A Review

artículo científico publicado en 2017

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial

artículo científico publicado en 2016

Lista de obras de Bryan Oronsky

A Case of Paraneoplastic Cushing Syndrome Presenting as Hyperglycemic Hyperosmolar Nonketotic Syndrome

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet.

A Review of Clinical Radioprotection and Chemoprotection for Oral Mucositis.

A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity?

A note on improved statistical approaches to account for pseudoprogression

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

CMET-46. INITIAL CLINICAL AND ADVANCED IMAGING OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I DOSE-ESCALATION TRIAL OF RRX-001 PLUS WHOLE BRAIN RADIATION FOR PATIENTS WITH BRAIN METASTASES

COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making

Cardioprotective Effect of Phase 3 Clinical Anticancer Agent, RRx-001, in Doxorubicin-Induced Acute Cardiotoxicity in Mice

Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets.

Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Cushing's Syndrome, Cortisol, and Cognitive Competency: A Case Report

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity

Episensitization: Defying Time's Arrow

Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor

Follow the ATP: tumor energy production: a perspective

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria

Going viral: a review of replication-selective oncolytic adenoviruses

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Just eat it: A review of CD47 and SIRP-α antagonism

Locally advanced rectal cancer: The past, present, and future

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors

Medical Machiavellianism: the tradeoff between benefit and harm with targeted chemotherapy

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

No patient left behind: The promise of immune priming with epigenetic agents

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent

Pulmonary Tumor Thrombotic Microangiopathy: A New Paraneoplastic Syndrome?

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets

RRx-001 protects against cisplatin-induced toxicities.

RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition

RRx-001, A novel dinitroazetidine radiosensitizer

RRx-001, a novel clinical-stage chemosensitizer, radiosensitizer, and immunosensitizer, inhibits glucose 6-phosphate dehydrogenase in human tumor cells

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm

Results from a biomarker study to accompany a phase II trial of RRx-001 with reintroduced platinum-based chemotherapy in relapsed small cell carcinoma

Rewriting the epigenetic code for tumor resensitization: a review.

Rockets, radiosensitizers, and RRx-001: an origin story part I.

Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study.

Superior Vena Cava Syndrome in a Patient with Small-Cell Lung Cancer: A Case Report

TGF-beta: a master immune regulator

Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.

The Case of a Zebra That Was Misdiagnosed as a Horse: Pulmonary Tumor Thrombotic Microangiopathy, a New Paraneoplastic Syndrome, Mimicking PD-1-Induced Pneumonitis

The Development Of RRx-001, A Novel Nitric-Oxide-Mediated Epigenetically Active Anticancer Agent.

The capacity of red blood cells to reduce nitrite determines nitric oxide generation under hypoxic conditions

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry

The macrophage stimulating anti-cancer agent, RRx-001, protects against ischemia-reperfusion injury

The war on cancer: a military perspective

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents

What's New in SCLC? A Review

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial